Olfr804 is a member of the olfactory receptor family, which are G protein-coupled receptors (GPCRs) crucial for the detection of odorant molecules and the initiation of the olfactory signal transduction pathway. The activation of olfactory receptors, including Olfr804, typically involves the binding of specific odorant molecules. This binding induces conformational changes in the receptor, facilitating interaction with G proteins and triggering a series of intracellular signaling events leading to odor perception. The exact ligands and complete range of physiological functions of Olfr804, as with many olfactory receptors, are not fully characterized. This is reflective of the complexity and diversity within the olfactory system. The mechanisms of activation for Olfr804, similar to other GPCRs, are influenced by the cellular environment and various signaling molecules. A critical pathway in GPCR regulation is the cyclic adenosine monophosphate (cAMP) signaling pathway. cAMP acts as a secondary messenger and plays an essential role in numerous cellular functions, including the modulation of GPCR signaling. The production of cAMP is regulated by adenylate cyclase, which converts ATP into cAMP in response to external stimuli. Accumulation of cAMP activates protein kinase A (PKA), resulting in the phosphorylation of target proteins, including GPCRs. This phosphorylation can affect the receptor's sensitivity to ligands, altering its activation dynamics. Moreover, cAMP can modulate other signaling pathways that intersect with GPCR signaling, thereby indirectly influencing the activity of receptors such as Olfr804.
Phosphodiesterases (PDEs), which are responsible for degrading cAMP, play a crucial role in maintaining its intracellular concentration. Inhibiting PDEs can lead to an increase in cAMP within the cell, indirectly affecting GPCR signaling. This increase in cAMP, due to PDE inhibition, can indirectly modulate the activity of Olfr804 through various mechanisms, including changes in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Additionally, compounds that directly increase cAMP levels, such as adenylate cyclase activators or β-adrenergic receptor agonists, can also indirectly affect the activity of Olfr804. These interactions demonstrate the complexity of GPCR regulation and highlight the potential of various chemical compounds to modulate the activity of receptors like Olfr804 indirectly. In conclusion, the study of Olfr804 activation is crucial for understanding the olfactory system and the broader role of GPCRs in sensory perception and physiological processes. The intricate interplay between different cellular components and signaling molecules, along with the potential for modulation by external compounds, underscores the complexity and importance of these receptors in sensory perception and cellular communication.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a β-adrenergic agonist, raises intracellular cAMP via adenylate cyclase activation. Increased cAMP could indirectly modulate Olfr804 signaling pathways, enhancing receptor activation and signal transduction. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels, potentially influencing Olfr804 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, an endogenous catecholamine, stimulates α and β-adrenergic receptors, increasing cAMP via adenylate cyclase. This surge in cAMP could indirectly affect Olfr804 activation, potentially enhancing its activity through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a phosphodiesterase 4 (PDE4) inhibitor, increases cAMP levels. Elevated cAMP may enhance Olfr804 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide, a selective PDE3 inhibitor, raises intracellular cAMP, potentially influencing Olfr804 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol, a β2-adrenergic agonist, increases cAMP levels via adenylate cyclase activation. This increase might boost Olfr804 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr804 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr804 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr804 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy. | ||||||